Lupus Trial, Recruiting NCT06167174 Sponsor: Chinese SLE Treatment And Research Group Condition: Lupus
Back to Lupus

Lupus Trial, Recruiting

NCT06167174
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged between 16 and 60 years old
  • People who have been diagnosed with Systemic Lupus Erythematosus (SLE/Lupus) according to a specific set of medical guidelines from 2012
  • People who have had a kidney biopsy within the last 6 months showing a specific type of lupus-related kidney disease (classified as type III, IV, V+III, or V+IV)
  • People whose kidney biopsy shows signs of active disease
  • People who have had two urine protein tests within two weeks, both showing protein levels above 1g in a 24-hour collection
  • People who have either never received steroid or immune-suppressing medications, or who have been on a stable standard treatment for more than one month without changes (confirm with trial site for exact medication types and doses)
  • People who have given their written consent to participate

Who may not be able to join:

  • People who have another connective tissue or autoimmune disease alongside their lupus
  • People whose lupus is affecting the brain or nervous system, lungs (bleeding), eyes (retinal damage), lung blood vessels, or other major organs severely
  • People who are pregnant or breastfeeding
  • People who currently have an infection that requires antibiotic or antiviral treatment
  • People who have a kidney disease unrelated to lupus
  • People with a very low platelet count (a blood cell type important for clotting) below a certain level
  • People with certain liver enzyme levels that are elevated above the normal range
  • People with certain liver or blood fat (cholesterol/lipid) markers that are significantly above the normal range
  • People the trial investigators consider unsuitable for other reasons (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Xinping Tian, MD, Peking Union Medical College Hospital

Phone: 86-13691165939

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Chinese SLE Treatment And Research Group
Registry
ClinicalTrials.gov
Start date
5 December 2023
Est. completion
5 December 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Treatment response of patients

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov